Takeda makes European appointments

Hires ceo of Takeda Pharmaceuticals Europe and md of Takeda Global R&D Centre Europe

On 1 April, Trevor Smith will assume the role of chief executive of Takeda Pharmaceuticals Europe, the Japanese firm’s London, UK-based subsidiary for pan-European sales and marketing. He is currently vice president, international strategy at Takeda Pharmaceutical Company.

At the same time, Stuart Dollow will join the company as managing director of Takeda Global Research & Development Centre Europe, Takeda’s pharmaceutical development subsidiary, headquartered in London.

Smith brings more than 30 years of pharmaceutical experience to his role. He has worked at Takeda for more than 10 years in various positions, including managing director of Takeda UK and vp, New Portfolio for Takeda Pharmaceuticals Europe.

Smith previously worked for Servier Laboratories as md of Servier South Africa, based in the UK. He also worked as vp of Northern Europe, based at the company’s parent organisation in Paris, France.

Smith will succeed Erich Brunn, who is retiring. Brunn joined the company in 2001 as president of Takeda’s German subsidiary.

Dollow has more than 20 years of pharmaceutical industry experience in international clinical development and leadership in the US and Europe. He previously worked at Roche in the UK, GlaxoWellcome and GlaxoSmithKline in the UK and US, and joins Takeda from Norgine, where he was chief development officer.

Dollow has experience in multiple therapeutic areas, including cardiovascular and metabolic disease, respiratory and oncology. He will succeed Steve Coles, who retired today (31 March).

You may also like

Finance

Takeda Pharmaceutical to acquire GammaDelta Therapeutics

Abingworth was the founding investor in GammaDelta and provided initial seed funding as part of the company’s creation in 2016
Finance

Takeda to evaluate Aptamer Group reagents for drug development

Based on oligonucleotide molecules, Optimers (which the company describes as optimised aptamer reagents) can bind specifically to a target molecule to act as an antibody alternative
Finance

Adaptate Biotherapeutics raises $18 m in Series A2 funding

The financing will also support the company’s expansion, including further recruitment and increased laboratory and office space
Finance

Novadiscovery enters clinical simulation collaboration with Takeda

This agreement builds on an existing relationship between the companies that began in 2017
Research & Development

Evox Therapeutics and Takeda sign multitarget rare disease collaboration

Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox’s proprietary exosome technology
Finance

Charles River secures milestone deals with Takeda and HemaCare

The laboratory giant inks deal with global Japanese drugmaker and completes acquisition of the cell and gene products manufacturer
Media

Only a handful of pharma companies are developing the urgently needed new medicines for the poor

The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical companies and on five diseases
Subscribe now